General and statistical hierarchy of appropriate biologic endpoints.

Oncology (Williston Park, N.Y.)

Volumn 20, Issue 6 Suppl 5, 2006, Pages 5-9

  Sargent, Daniel ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ARTICLE; BIOASSAY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG APPROVAL; HUMAN; MICROBIOLOGY; MORTALITY; NEOPLASM; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG APPROVAL; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 33750096548     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)